Amit Gokhale1, Lidia Glodzik1, Songtao Liu1, Juchen Hirsch2, L Achtnichts2, A Monsch3, Achim Gass2, Oded Gonen1
1Radiology, NYU School of Medicine, New York, NY, USA; 2Neurology, University of Basel, Basel, Switzerland; 3Neurology, University of Basel, Basel, Bas, Switzerland
The very large - in the millions and fast-growing number of Alzheimers disease (AD) patients motivates a search of preferably non invasive markers that could detect the diseases at its earliest possible stage. Since, AD is known to be a neuronal dysfunction; MR spectroscopy has a specific marker for it the N-acetylaspartate (NAA). Furthermore, since AD is a diffuse disorder, whole-brain NAA (WBNAA) spectroscopy is the most appropriate tool. In this study we applied WBNAA to controls, Mild cognitively impaired individuals (believed to be early AD) and AD patients to quantify the detectable differences between these three populations.